Inspira Technologies 2022 Acute Respiratory Care Investor Presentation

Inspira Technologies presents its novel extracorporeal respiratory support system (ART) designed to support non-invasive ventilation patients with acute respiratory failure. The company highlights pre-clinical evidence from swine studies demonstrating the system's ability to rebalance oxygen and CO2 levels, with strategic deployment agreements across Europe and the U.S. targeting up to $386 million in revenue over seven years pending regulatory approval.